Cellular Biotechnology Lab (@LAB_BIOC) header
Cellular Biotechnology Lab (@LAB_BIOC) profile picture

Cellular Biotechnology Lab at ISCIII Pediatric Cancer / Advanced Therapy / Immunotherapy https://teapaw.org/t.co/kalE8dtJnL

Madrid - Spain
Joined April 2023
Join us at ISCIII !!! Focis on Advanced Therapies in pediatric cancer.
38
oc At ESGCT 2025, @Fesisisimo presented our results from a clinical trial of ALOCELYVIR in children with brain tumors, in a strong collaboration with Dr Álvaro Lassaletta and his team at Hospital Niño Jesús. @APUpablougarte @AFANION_ @SaludISCIII
3
4
745
We are looking for a postdoctoral researcher with solid expertise in tumor immunology to join our group BIOC (ISCIII), dedicated to immuotherapies on pediatric cancer research. This opportunity is linked to the AECC postdoctoral fellowships. Feel free to contact us !!
2
2
2
228
Our group is presenting our latest results at the CICON25 Congress in Utrecht, a meeting with a special focus on immunotherapy of cancer @SaludISCIII
1
2
4
173
In the pilot phase, no clinical responses were observed in 18 patients unselected TILs. However, when TILs were selected for neoantigen recognition, 3 responses were seen in 39 patients (7.7%). Pembrolizumab was added, and 8 objective responses were seen in 34 patients (23.5%)
3
4
210
Osteosarcoma remains a highly aggressive bone malignancy with limited therapeutic options, necessitating novel treatment strategies. Minireview: frontiersin.org/journals/imm…
78
EsoBiotec SA has launched a clinical trial for ESO-T01, in vivo BCMA CAR-T therapy for multiple myeloma ESO-T01 reprograms T cells directly using the ENaBL platform, which uses a viral vector said to be “immune shielded” via the removal of MHC1 and the overexpression of CD47
1
1
2
248
T cell receptor precision editing of regulatory T cells for celiac disease. Authors generated gluten- reactive HLA- DQ2.5–restricted CD4+ engineered eTregs. e Tregs hold therapeutic potential for restoring gluten tolerance in their mice model. science.org/doi/epdf/10.1126…
2
4
158
"Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma." Nat Med 2025 Bambino Gesù Children’s Hospital, Italy. nature.com/articles/s41591-0…
3
5
331
Phase I using B7-H3 CAR T cells for children with recurrent or refractory CNS tumors and DIPG. Patients were treated on four escalating dose regimens: 1-10 × 10_7 CAR T cells per dose. Authors did not find CRS complicating ICV infusions. nature.com/articles/s41591-0…
4
7
427
Phase II clinical trial CT041-ST-01. An autologous CAR T-cell against Claudin18.2 (“satri-cel”, CT041) in advanced gastric cancers. Statistically significant improvement in progression-free survival (PFS) as compared to classic treatment. carsgen.com/en/news/20241230…
2
2
247
Tumor-associated macrophages were the primary source of antigenic exposure governing the terminally exhausted T (Tex_term) to stem-like progenitor-exhausted T (Tex_prog) transition. TAM depletion promoted responsiveness to αPD1 immunotherapy. cell.com/action/showPdf?pii=…
1
63
Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from an open-label phase I/II and long-term clinical trials. Río, P.,.... , Bueren, J.A.. The Lancet, 2024, Vol 404 thelancet.com/journals/lance…
7
1
14
609
▶️New paper: "Deletion of the RGD motif from the penton base in oncolytic adenoviruses enhances antitumor efficacy of combined CAR T cell therapy" We design ISC301, a novel oncolytic adenovirus, 🧬engineered to enhance immunotherapies. 💉 sciencedirect.com/science/ar…
5
2
17
1,628
Adaptimmune receives FDA accelerated approval of TECELRA, the first approved engineered cell therapy for a solid tumor: unresectable or metastatic synovial sarcoma expressing the MAGE-A4 antigen. adaptimmune.com/investors-an…
5
11
349
FDA Accepts Mesoblast’s BLA for Ryoncil (remestemcel-L) in Children With Steroid-Refractory Acute GVHD Remestemcel-L is an investigational therapy comprising culture expanded MSC derived from the bone marrow of an unrelated donor. globenewswire.com/news-relea…
1
3
165
Satricabtagene autoleucel (satri-cel)/CT041 is an autologous CAR T cell targeting CLDN18.2 Nat Med (2024). doi.org/10.1038/s41591-024-0…
In the largest report of #CARTcells in patients with solid tumors, autologous CLDN18.2-targeting CART therapy had overall response of 42.2% and disease control rate of 91.1% in patients with advanced CLDN18.2-positive gastrointestinal cancers nature.com/articles/s41591-0…
2
4
191